Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma
- PMID: 20151824
- DOI: 10.1089/thy.2009.0187
Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma
Abstract
Background: Few reports have examined the use of recombinant human thyroid-stimulating hormone (rhTSH) for ablation of postsurgical thyroid remnants after low-dose radioactive iodine (RI) therapy, compared with conventional thyroid hormone withdrawal. We investigated whether patient preparation using rhTSH was comparable to conventional thyroid hormone withdrawal with respect to efficacy of postsurgical remnant ablation in low-risk patients receiving a 30 mCi RI. In addition, we also evaluated the impact of rhTSH (rhTSH vs. conventional thyroid hormone withdrawal) on quality of life (QoL) of thyroid cancer patients undergoing RI ablation.
Methods: This study included three groups of patients, enrolled consecutively. From February 2006 to March 2007, 291 patients were enrolled and randomized, after total thyroidectomy: (1) withdrawal of levothyroxine (LT4) for 4 weeks (T4-WD Group, n = 89), (2) withdrawal of LT4 for 4 weeks plus 2 weeks on and then 2 weeks off liothyronine (LT3) (T3-WD Group, n = 133), and (3) rhTSH administration (rhTSH Group, n = 69). QoL was determined at the time of ablation.
Results: Patients in the three groups did not differ significantly in baseline characteristics or tumor, node and metastasis (TNM) staging. In all study groups, serum TSH levels showed very good stimulation (mean, 82.24 +/- 18.21 mU/L), without significant between-group differences (p = 0.5213). Follow-up examinations were performed 12 months after ablation to assess ablation outcome in each group by 131 whole body scans (WBSs), serum thyroglobulin measurement after TSH stimulation, and neck ultrasonography. The successful ablation rate was 91.0% in T4-WD Group, 91.7% in T3-WD Group, and 91.3% in rhTSH Group, without significant between-preparation differences (p = 0.2061). QoL was better preserved in rhTSH Group than in T4-WD and T3-WD Groups (p < 0.0001). However, there was no QoL difference at the time of ablation between T4-WD and T3-WD Groups.
Conclusions: Our study indicates that use of rhTSH preserves QoL in patients undergoing RI ablation and affords an ablation success rate comparable to that seen after thyroid hormone withdrawal. Notably, ablation preparation using withdrawal of LT3 for 2 weeks did not prevent development of profound hypothyroidism, as also occurred when LT4 alone was withdrawn for 4 weeks.
Similar articles
-
Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.J Clin Endocrinol Metab. 2003 Sep;88(9):4110-5. doi: 10.1210/jc.2003-030298. J Clin Endocrinol Metab. 2003. PMID: 12970272 Clinical Trial.
-
Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study.Clin Endocrinol (Oxf). 2009 Jul;71(1):115-23. doi: 10.1111/j.1365-2265.2008.03424.x. Epub 2008 Sep 18. Clin Endocrinol (Oxf). 2009. PMID: 18803678 Clinical Trial.
-
Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal.J Clin Endocrinol Metab. 2010 Jul;95(7):3283-90. doi: 10.1210/jc.2009-2528. Epub 2010 Apr 14. J Clin Endocrinol Metab. 2010. PMID: 20392868 Clinical Trial.
-
rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.Endocr Relat Cancer. 2005 Mar;12(1):49-64. doi: 10.1677/erc.1.00830. Endocr Relat Cancer. 2005. PMID: 15788638 Review.
-
How the availability of recombinant human TSH has changed the management of patients who have thyroid cancer.Nat Clin Pract Endocrinol Metab. 2007 Sep;3(9):641-50. doi: 10.1038/ncpendmet0594. Nat Clin Pract Endocrinol Metab. 2007. PMID: 17710085 Review.
Cited by
-
Comparison of day 3 and day 5 thyroglobulin results after thyrogen injection in differentiated thyroid cancer patients.Ther Adv Endocrinol Metab. 2018 Jun;9(6):177-183. doi: 10.1177/2042018818770108. Epub 2018 Apr 17. Ther Adv Endocrinol Metab. 2018. PMID: 29854387 Free PMC article.
-
Gut microbiome versus thyroid cancer: Association and clinical implications (Review).Oncol Lett. 2025 May 27;30(1):368. doi: 10.3892/ol.2025.15114. eCollection 2025 Jul. Oncol Lett. 2025. PMID: 40487754 Free PMC article. Review.
-
Five-year longitudinal evaluation of quality of life in a cohort of patients with differentiated thyroid carcinoma.J Zhejiang Univ Sci B. 2011 Mar;12(3):163-73. doi: 10.1631/jzus.B1000382. J Zhejiang Univ Sci B. 2011. PMID: 21370500 Free PMC article.
-
Restoration of euthyroidism with levothyroxine: implications of etiology of hypothyroidism and the degree of residual endogenous thyroid function.Front Endocrinol (Lausanne). 2022 Jul 22;13:934003. doi: 10.3389/fendo.2022.934003. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35966075 Free PMC article. Review.
-
Role of Recombinant Human Thyrotropin (rhTSH) in the Treatment of Well-Differentiated Thyroid Cancer.Indian J Surg Oncol. 2012 Sep;3(3):182-9. doi: 10.1007/s13193-011-0115-1. Epub 2011 Dec 20. Indian J Surg Oncol. 2012. PMID: 23997506 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials